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Histone deacetylase 3 (HDAC3), a chromatin-modi-
fying enzyme, requires association with the deacety-
lase-containing domain (DAD) of the nuclear receptor
corepressors NCOR1 and SMRT for its stability and
activity. Here, we show that aldose reductase (AR),
the rate-limiting enzyme of the polyol pathway, com-
petes with HDAC3 to bind the NCOR1/SMRT DAD.
Increased AR expression leads to HDAC3 degrada-
tion followed by increased PPARg signaling, result-
ing in lipid accumulation in the heart. AR also
downregulates expression of nuclear corepressor
complex cofactors including Gps2 and Tblr1, thus
affecting activity of the nuclear corepressor complex
itself. Though AR reduces HDAC3-corepressor com-
plex formation, it specifically derepresses the reti-
noic acid receptor (RAR), but not other nuclear
receptors such as the thyroid receptor (TR) and liver
X receptor (LXR). In summary, this work defines a
distinct role for AR in lipid and retinoid metabolism
through HDAC3 regulation and consequent dere-
pression of PPARg and RAR.
INTRODUCTION
Acetylation orchestrates genome-wide transcriptional changes
through chromatin decondensation and is the net result of the
opposing actions of histone acetyl transferases (HATs) and his-
tone deacetylases (HDACs). HATs and HDACs form large acti-
vator and repressor complexes, resulting in transcriptional
gene regulation (Kouzarides, 2000; Sterner and Berger, 2000).
HDAC3, belonging to class I HDAC family, is specifically re-
cruited to the SMRT (silencing mediator of retinoid and thyroid
receptor) complex, where it interacts with the DAD (deacetylase
activation domain) domain of either NCOR1 (nuclear core-
pressor 1) or SMRT (nuclear corepressor 2; Guenther et al.,
2001). This domain in NCOR1/SMRT activates HDAC3 and is
essential for the maintenance of normal circadian metabolic
physiology. Reductions in HDAC3 expression/activity influence
lipogenesis in mouse models (Liu et al., 2013; Sun et al., 2011,This is an open access article under the CC BY-N2012). Cardiac-specific deletion of HDAC3 leads to severe car-
diac hypertrophy due to myocardial lipid accumulation and
elevated triglyceride levels (Montgomery et al., 2008). De novo
HDAC3 synthesis is an ongoing process, and this protein is
degraded if unbound to the corepressors. The possibility of co-
occurrence of corepressors (NCOR1 and SMRT) in the same
complex has been refuted (Zhang et al., 2002). Hence, specific
HDAC3-nuclear repressor complex is achieved by dissociation
of the existing corepressor complex followed by de novo synthe-
sis of both the corepressor and HDAC3 protein in the cytoplasm
(Guenther et al., 2000; Guo et al., 2012).
The HDAC3-corepressor complex represses several nuclear
receptors including thyroid receptor (TR), retinoic acid receptor
(RAR), vitamin D receptor (VDR), androgen receptor (AR), gluco-
corticoid receptor (GR), and others (Dwivedi et al., 1998; Shang
et al., 2000; Wagner et al., 2003; Wong et al., 2014). Upon ligand
binding, the HDAC3-NCOR1/SMRT complex dissociates,
paving the way for activator complexes to bind the receptors
and activate gene transcription (Atsumi et al., 2006; Ishizuka
and Lazar, 2003; Li et al., 2011). Despite their critical roles in
controlling gene expression, factors involved in regulation of
repressor complex dissociation remain unidentified.
Aldose reductase (AR), the rate-limiting enzyme of the polyol
pathway, plays a critical role in mediating cardiovascular com-
plications in diabetes, aging, and I/R injury (Ananthakrishnan
et al., 2011; Hwang et al., 2004; Ramasamy and Goldberg,
2010; Ramasamy et al., 1997). Because mice display low-AR
expression and activity, transgenic expression of human AR
(hAR) in mice is essential to recapitulate the activity and
expression levels observed in humans, including the dia-
betes-associated cardiac complications (Ramasamy and Gold-
berg, 2010). In mice, cardiomyocyte-specific overexpression of
hAR (myosin heavy chain [MHC]-hAR) causes increased cer-
amide levels and accompanying heart failure in ischemic and
aging hearts (Son et al., 2012). Furthermore, our recent studies
demonstrated decreased HDAC activity, increased acetylation
of hypoxia-responsive Egr-1, and induction of inflammatory
genes in hAR-overexpressing diabetic apoE-null mice (Vedan-
tham et al., 2014). These studies led us to investigate whether
hAR-driven lipid changes in cardiac cells are mediated, in part,
via HDACs.
Our studies revealed that hAR expression in mice hearts leads
to a decrease in HDAC3 levels accompanied by an increase inCell Reports 15, 181–196, April 5, 2016 ª2016 The Authors 181
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PPARg activity, thereby contributing to lipid-enriched environ-
ment. hAR expression leads to reduced HDAC3 corepressor
complexes with consequent increases in RARB in the nucleus
and derepression of its target gene expression. The observed
degradation of HDAC3 was due, in part, to competition between
hAR and HDAC3 for interaction with the DAD domain of SMRT/
NCOR1. Our findings reveal a role for hAR as a dissociation fac-
tor acting upon the HDAC3-corepressor complex, thereby spe-
cifically derepressing RAR and expression of its target genes.
RESULTS
hAR Overexpression Leads to Lipid Accumulation
To elucidate mechanisms by which hAR drives lipid accumula-
tion in the heart, we performed comprehensive measurements
of triglycerides, fatty acids, ceramides, and carnitines in hearts
and plasma of cardiomyocyte-specific hAR (MHC-hAR)-ex-
pressing mice, global AR knockout (ARKO), and non-transgenic
littermates (wild-type [WT]). Left ascending coronary artery liga-
tion followed by 48 hr of reperfusion (LADp48h) was used as an
ischemia-reperfusion (I/R) model, and the tissues were har-
vested at 48 hr post-surgery (LADp48h). We observed a 2-fold
increase in serum and myocardial triglycerides in MHC-hAR
mice compared toWT, whereas in ARKOmice, triglyceride levels
were lower or comparable to WT subjected to I/R (Figures S1A
and S1B). Increased serum-free fatty acids levels were observed
in MHC-hAR after I/R, though the increase was observed in
ARKO I/R mice as well (Figure S1C). We confirmed triglyceride
accumulation in hAR-expressing H9c2 cells (rat myoblast cell
line; Figure S1D). Under basal conditions (in the absence of
I/R), we observed no changes in triglyceride, whereas free fatty
acids were increased in serum of MHC-hAR mice versus WT
and the levels were comparable in WT and ARKO mice (Figures
1A and 1B). Interestingly, the cardiac triglyceride levels were
doubled in MHC-hAR mice compared to WT and ARKO mice
(Figure 1C). Comprehensive measurements of the lipid species
using mass spectrometry revealed significant increases in dele-
terious C14, C18:0, C20:0, C22, and C24:0 ceramide species
(Figure 1D), whereas medium- and long-chain acyl carnitines
showed an increasing trend in MHC-hAR versus WT hearts (Fig-
ure 1E). Transcript levels of fatty acid transporters Cd36 and
Fatp1 were increased in MHC-hAR hearts (Figure 1F). Whereas
the transcript levels of genes responsible for lipid synthesis
were not different (Figure 1G), the genes essential for fatty acid
oxidation (Lipe and Pnpla2) were 40% lower in MHC-hAR hearts
versus WT hearts (Figure 1H). Transcripts of fatty acid oxidation
genes were increased by 2-fold in ARKO mice compared to WTFigure 1. AR Overexpression Leads to Lipid Accumulation
Hearts from normally fed young mice were used.
(A–C) Serum triglyceride (n = 7 mice/group; A), serum free fatty acids (n = 7–10 mi
(n = 6 mice/group) using biochemical assays.
(D and E) Cardiac ceramide and acyl carnitines levels were measured by mass s
(F–H) qRT-PCR analysis of genes involved in fatty acid transport, synthesis, and
(I) Fatty acid uptake and oxidation in hearts were measured using [9,10 (N)-3H] p
(J) Heatmap of adipogenesis PCR array from the heart tissues (n = 4 mice/group
(K) qRT-PCR analysis of Ppar genes from heart tissue (n = 6 mice/group).
See also Figure S1F.hearts (Figure 1H). Measurements of 3H-palmitate uptake and
oxidation revealed marginal increase in fatty acid uptake (Fig-
ure 1I) and reduction in fatty acid oxidation (Figure 1I) in
MHC-AR-expressing hearts. We observed 1.5-fold increase in
triglyceride content in MHC-hAR hearts compared to WT hearts
(Figure S1E). Same trend of reduced 3H-fatty acid oxidation was
observed in adenovirally transduced hAR-expressing H9c2
(Ad-hAR) cells compared to the GFP-transduced (control) cells
(3H-fatty acid oxidation was 1.39 ± 0.1 mmoles/106 cells in con-
trol versus 0.72 ± 0.1 mmoles/106 cells in Ad hAR; p < 0.05).
Taken together, these results suggested the lipid accumulation
observed in MHC-hAR mice is mainly due to reduced oxidation
in MHC-hAR hearts. RT-PCR array studies revealed an upregu-
lation of several of the PPARg target genes, including AdipoQ,
Cfd, Leptin, and Fabp4 in MHC-hAR hearts compared to WT,
and a downregulation of these PPARg target genes in ARKO
mice (Figure 1J). Real-time PCR analysis of PPAR isoforms
(a, b, and d) revealed a 2.5-fold increase in Pparg mRNA in
MHC-hAR mice and a concordant reduction in ARKO mice (Fig-
ure 1K), whereas Ppara and dwere unaffected. Increase in Pparg
mRNAwas also observed in Ad-hAR cells compared to the GFP-
transduced (control) cells (Figure S1F).
Increased hAR Mediates HDAC3 Downregulation and
Increased PPARg
Because our previous findings linked hAR expression to
increased acetylation of Egr-1 and induction of inflammatory
genes, we investigated whether hAR-driven lipid changes are
mediated via acetylation (Vedantham et al., 2014). Measure-
ments of total HDAC activity from the nuclear lysates revealed
a 35% reduction in HDAC activity but no significant change in to-
tal HAT activity in MHC-hAR versus WT hearts (Figures 2A and
2B). Western blot analysis of WT, MHC-hAR, and ARKO heart ly-
sates revealed increased histone H4 acetylation in MHC-hAR
mice and reduced histone H4 acetylation in ARKO mice. No
significant changes were observed in histone H3 acetylation
(Figure 2C). We assessed individual histone modifications
and observed significant increases in H4K8Ac and H3K27Ac
in MHC-hAR hearts, whereas the other modifications like
H3K9Ac, H3K14Ac, H3K18Ac, and H4K5Ac were not signifi-
cantly changed or were decreased (Figures 2D and 2E). In Ad-
hAR-expressing H9c2 cells, decreased HDAC activity and
increased histone acetylation at the H4K5 and H4K8 sites was
observed (Figures S2A–S2C). Taken together, these data sug-
gest that increased acetylation observed in cells and tissue
due to hAR expression was the result of decreased HDAC activ-
ity, mainly at the histone H4K8 site. To elucidate the HDACsce/group; B), and cardiac tissue triglyceride measurements (C) were measured
pectrometry (n = 5 mice/group).
oxidation from the cardiac tissue of mice (n = 6 mice/group).
almitate (n = 5/group).
).
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Figure 2. AR Overexpression Leads to Reduced HDAC3
Nuclear fractions were isolated from 2-month-old WT, MHC-hAR, and ARKO mice hearts.
(A) HDAC activity (n = 6 mice/group).
(B) HAT activity (n = 6 mice/group).
(C) Quantification of acetylated H3 and H4 histones normalized to total H3 and H4.
(D) Western blot analysis and quantification. Acetyl H3 modifications normalized to total H3 are shown.
(E) Acetyl H4 modifications normalized to total H4.
(F) Western blot analysis of cardiac total lysates using HDAC3 antibody, normalized to b-actin.
(G) Western blot analysis of cardiac nuclear lysates using CEBPa and PPARg antibody, normalized to TBP (n = 3/group).
(H) qRT-PCR analysis of PPARg target genes using cardiac tissues (n = 6 mice/group).
See also Figures S2 and S3.
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responsible for increased acetylation, we performed HDAC
profiling in Ad-hAR H9c2 cells. We found no changes in HDAC
1, 2, and 10; increases in HDAC 6, 8, and 11; and reduced
HDAC 3 and 4 (Figure S2D). We observed 40% reduction in
HDAC3 protein level in cells expressing hAR versus controls (Fig-
ure S2E). These results in hAR cells were recapitulated in hearts
from MHC-hAR mice (Figure 2F).
hAR Activates PPARg Target Genes
HDAC3 serves as a repressor of many transcription factors such
as MEF2, KLF6, PPARg, Runx2, CEBP, TFII-1, and NF-kB, and a
reduction in HDAC3 can lead to activation of these factors (Gao
et al., 2006; Gre´goire et al., 2007; Li et al., 2005; Paz-Priel et al.,
2011; Ren et al., 2013; Schroeder et al., 2004; Tussie´-Luna et al.,
2002). We observed increased PPARg and reduced CEBPa
expression in the nuclear fractions of MHC-hAR hearts compared
to WT and ARKO, indicating increased PPARg to be the driving
force for increased lipid accumulation by hAR (Figure 2G). No sig-
nificant changes were observed in RUNX2 levels (Figure 2G). Pu-
rity of cytoplasmic and nuclear fraction was verified using specific
markers by western blot analysis (Figure S2G). Real-time PCR
analysis of PPARg target genes revealed increased AdipoQ,
Fsp27, andAcacbexpression inMHC-hARhearts, thusconfirming
the activation of PPARg in vivo (Figure 2H). Consistently, in hAR-
expressing H9c2 cells, we observed increases in PPARg protein
(Figure S2E). Out of seven PPARg target genes examined, five of
the genes involved in fatty acid metabolism including Fasn,
Cd36, Fatp1, AdipoQ, and Sirt3 were upregulated, indicative of
enhanced PPARg transcriptional activation, although there were
no significant changes in Slc2a4 and Srebf1 (Figure S2H). A 2.5-
fold increase in protein levels of CD36, a prototype target gene
of PPARg, in hAR versus control cells was observed (Figure S3A).
Chromatin immunoprecipitation (ChIP) studies using the PPARg
antibody revealed increased binding to the promoter of the Cd36
gene in cells expressing hAR versus control (Figure S3B). Thus,
these results confirmed the decreased HDAC3 protein level and
enhanced PPARg activation in hAR-expressing cells and mice.
hAR-Mediated Lipid Changes in Aging and Diabetes
We then assessed the effect of HDAC3 in globally expressing
transgenic hAR (TghAR) mice and observed reduced HDAC3 in
TghAR mice and elevated HDAC3 protein levels in ARKO mice
(Figure 3A). To demonstrate that pathological conditions, which
lead to increased AR activity, can subsequently reduce HDAC3
and activate PPARg, we examined hearts from I/R, aging mice,
and diabetic mice. We observed AR-mediated changes both in
HDAC3 and PPARg in I/R (Figure 3B) and aging hearts (Fig-
ure 3C). We observed increases in cardiac triglyceride levels in
aging hearts compared to control (Figures 3C and 3D). Similar
changes in HDAC3 and PPARgwere observed in diabetic mouse
hearts (DM) compared to the non-diabetic hearts (NDM) (Fig-
ure 3E). DM hearts showed a non-significant trend for increased
triglyceride accumulation (Figure 3F). Kidney lysates from TghAR
mice showed reduced HDAC3 expression (Figure 3G). Reduced
HDAC3 expression was noted in hAR-transfected human umbil-
ical cord endothelial cells (HUVEC), human aortic endothelial
cells (HAEC), and HEK293T cells (Figure 3H). These data indi-
cated that AR-mediated changes in HDAC3 and PPARg arenot only induced by exogenous overexpression but also seen
in pathological (diabetes and I/R) and physiological (aging) con-
ditions and in other tissue and cell types as well.
hAR Competes with HDAC3 for DAD
We then assessed the possibility that the mechanism underlying
HDAC3 downregulation by hAR was transcriptionally regulated.
Real-time PCR analysis of Hdac3 and its corepressors Ncor1
and Smrt did not reveal any differences, indicating that it was
not at the transcriptional or corepressor level in tissue or cells
(Figures 4A and S3C). To determine the role of ubiquitin-medi-
ated proteasomal degradation, we treated Ad-hAR cells with
MG132, a potent proteasome inhibitor, and found no recovery
of HDAC3 expression (Figure 4B). Interestingly, MG132 treat-
ment in Ad-hAR cells revealed an additional lower-molecular-
weight band when probed with the HDAC3 antibody. To confirm
that the additional bands in Ad-hAR cells were specific to
HDAC3, we employed two different (N- and C-terminal-specific)
HDAC3 antibodies. In both cases, we detected the presence of
the additional lower-molecular-weight HDAC3 band, indicating
HDAC3 cleavage in the presence of hAR (Figure 4C). Because
HDAC3 protein degradation appeared to be insensitive to
MG132, testing with other proteasome inhibitors revealed that
bortezomib prevented HDAC3 degradation, confirming that
HDAC3 undergoes cleavage through the ubiquitin-mediated
proteasome pathway (Figure 4D). To identify the underlying
mechanisms of enhanced proteasomal degradation, we probed
for a protein-protein interaction between AR and the HDAC3-
corepressor complex. Co-immunoprecipitation using HDAC3
antibody and probed for AR failed to show positive interaction,
whereas immunoprecipitation using NCoR1 or AR antibody
revealed a positive interaction (Figure 4E). Because core-
pressor-free HDAC3 has been shown to be prone to proteaso-
mal degradation (Guo et al., 2012), we hypothesized that AR
competes with HDAC3 to bind to the corepressor. To address
our hypothesis, we performed competition binding assays by
incubating equal amounts of the HDAC3-DAD-His complex
with increasing amounts of recombinant AR (r.AR) and precipi-
tated using Ni-NTA beads. As depicted, increasing AR displaces
the HDAC3 from the complex (Figure 4F). We then questioned
whether the interaction between AR andDADabrogates their ac-
tivity. We performed in vitro HDAC activity assays with the active
HDAC3 fraction (HDAC3 and GST-DAD; SMRT; r.HDAC3) and
hAR protein (r.AR). r.AR did not exhibit HDAC activity. When
r.AR was incubated with HDAC3, there was a 10% reduction in
HDAC activity (Figure 4G). To confirm the reduction in HDAC ac-
tivity was due to AR presence, we incubated r.HDAC3with either
purified BSA or recombinant ABCG1 protein and observed no
reduction in HDAC activity, suggesting that the reduction in ac-
tivity is specific to AR. Incubation of AR with HDAC3-DAD did
not lead to significant reductions in AR activity (Figure 4H),
whereas DAD in the absence of HDAC3 reduced AR activity by
30% (Figure 4H). Thus, these results confirm the interaction be-
tween AR and the DAD domain of nuclear corepressors.
L289-hAR Is Essential for DAD Interaction
Crystal structures of AR and the HDAC3-DAD complex have pre-
viously been elucidated (Watson et al., 2012; Wilson et al., 1993).Cell Reports 15, 181–196, April 5, 2016 185
Figure 3. AR-Mediated HDAC3 Downregulation Observed in Various Pathological Settings
Western blot analysis of cardiac lysates using specific antibodies to HDAC3, PPARg, AR, and b-actin.
(A and B) Hearts from 4-month-old mice obtained (A) from WT, TghAR, and ARKO (n = 5/group) and (B) from wild-type and mice subjected to left occlusion
ascending coronary artery ligation surgery post-48 hr (LADp48h) were used for western analysis (n = 6/group).
(C) Young and old hearts from wild-type mice (n = 5/group) were analyzed by western blots.
(D) Cardiac tissue triglyceride measurements from young and old mice (n = 4 mice/group).
(E and F) Six-month-old diabetic and non-diabetic mice lysates were used for western analysis (E), and their corresponding cardiac triglycerides (F) are shown
(n = 4 mice/group).
(G) Western blots on kidney lysates from wild-type and TghAR mice (n = 5 mice/group).
(H) HEK293, HAEC, and HUVEC cells transfected with GFP- or hAR-encoding plasmids in cells (n = 3).Overlapping the structures of AR and HDAC3-DAD using Pymol
program revealed a particular stretch of amino acids (30–39
amino acids [aa]) in HDAC3 resembling the residue (286–
293 aa) of AR. Analysis of this sequence indicated that the key
sites were 287, 289, and 291 of AR (Figure S3D). Three site-
directed mutants of hAR in the pTCN-Sport6 vector with Flag
tag were generated (T287A, L289A, and Y291A). Transfection186 Cell Reports 15, 181–196, April 5, 2016of wild-type hAR along with these mutants in HEK293 cells
showed that L289A maximally rescued the HDAC3 protein
whereas the wild-type and other twomutants failed to do so (Fig-
ure 5A). Co-immunoprecipitation using the Flag antibody fol-
lowed by probing with the NCOR1 antibody revealed that
L289A mutant fails to interact with NCOR1 (Figure 5B). Thus,
Leu 289 in hAR is essential for its interaction with the DAD
Figure 4. AR Interacts with the DAD of Nuclear Corepressors
(A) qRT-PCR analyzed for Hdac3, Ncor1, and Smrt transcripts from the cardiac tissues of MHC-hAR and wild-type littermates (n = 6 mice/group).
(B) Ad-GFP- or Ad-hAR-transduced cells were treated with 5 mM MG132 for overnight, 24 hr post-transfection. Expression of HDAC3 was evaluated using
western blot.
(C) Western blot analysis of MG132-treated cells with both N-terminal and C-terminal HDAC3-specific antibodies.
(D) Adenovirally transduced H9c2 cells were treated with one of the inhibitors—MG132 (5 mM), bortezomib (1 mM), and epoxomicin (1 mM)—overnight, and lysates
were analyzed for HDAC3 expression by western blot.
(E) Expression analysis of HEK293 lysates after immunoprecipitation with either HDAC3 or AR antibody and probed for NCOR1 (top). Immunoprecipitation with
NCOR1 antibody and probed for AR (bottom) is shown. Expression analysis of WT and MHC-hAR heart lysates after immunoprecipitation with either NCOR1
antibody and probed for AR (side) is shown.
(legend continued on next page)
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domain.We further confirmed the lack of interaction between the
L289A mutant and DAD by comparing AR activity in L289A
mutant and the wild-type hAR protein (Figure 5C). Furthermore,
L289A-hAR-expressing H9c2 cells failed to show increases in
Pparg target genes and triglycerides when compared to hAR-ex-
pressing cells (Figures S3E and S3F).
We next determined that DAD supplementation rescued the
reduction in HDAC3 activity in the presence of r.AR (Figure 5D).
To confirm the rescue of HDAC3 by modulation of NCOR1
expression, we performed retroviral-mediated transduction of
NCOR1 in H9c2 cells followed by adenoviral transduction with
GFP (control) or hAR. HDAC3 levels were rescued to that of
Ad-GFP cells, confirming that NCOR1 availability is the deter-
mining factor in HDAC3 degradation (Figure 5E). The transcript
levels of Pparg and its downstream target genes AdiopoQ,
Cd36, and Fatp1 were not increased and HDAC3 levels were
not lowered upon hAR expression in NCOR1-expressing cells
(Figure 5F), reaffirming the DAD availability as the criteria to
rescue HDAC3 degradation. Triglyceride measurement in
NCOR1 stably expressing H9c2 cells failed to show increased
accumulation despite hAR overexpression (Figure 5G). Treat-
ment of MHC-hAR hearts with theophylline enhanced HDAC3
expression without attenuating PPARg (Figure 5H). Taken
together, these data indicate that increasing HDAC3 along with
equivalent increases in NCOR1 may be required for repression
of PPARg (Figure 5H).
hAR Derepresses RAR Pathway
Immunoprecipitation of the nuclear corepressor complex using
the SMRT antibody followed by probing with HDAC3 revealed
reduced HDAC3-corepressor complex formation in Ad-hAR-ex-
pressing cells compared to control cells (Figure 6A). In addition
to HDAC3 and its corepressors, the HDAC3-corepressor com-
plex consists of cofactors including GPS2, TBL1, TBLX1, and
TBLXR1. GPS2 has been reported to interact with various
transcriptional factors including p53, LXR, MSH4, and MSH5.
Similar to GPS2, both TBL1 and TBLR1 are involved in transcrip-
tional regulation (Li and Wang, 2008; Oberoi et al., 2011;
Zhang et al., 2006). We observed that the expression of these
accessory cofactors essential for nuclear corepressor complex
formation including Gps2, Tbl1, and Tbl1xr were downregulated
in MHC-hAR mice (Figure 6B). Taken together, these data indi-
cate that reduced HDAC3-corepressor complex in MHC-hAR
mice is likely due to both HDAC3 degradation and cofactor
downregulation.
Nuclear receptors transduce ligand-mediated signals into
changes in expression of gene networks (Evans, 1988; Glass
and Rosenfeld, 2000; Mangelsdorf et al., 1995; Xu et al., 1999;
Yen et al., 2003). Nuclear receptors including TR, RAR, LXR,
and PXR form large molecular complexes with the HDAC3-nu-
clear corepressor complexes, binding DNA and repressing their
target genes. Because hAR expression reduces HDAC3-nuclear(F) Competition binding assay Ni-NTA agarose beads. Input control without beads
HDAC3 with increasing AR are shown.
(G) HDAC activity performed with the purified recombinant proteins obtained as
(H) AR activity performed with the purified recombinant proteins (n = 6). Specific
protein (n = 9).
188 Cell Reports 15, 181–196, April 5, 2016corepressor complexes, we hypothesized that the nuclear re-
ceptors that rely on HDAC3-nuclear corepressor for their repres-
sion will be derepressed. To test this, we probed for TR target
genes, both positively (Myh6 and Serca2a) and negatively
(Myh7 and Ncx1) modulated by thyroid hormone (Reed et al.,
2000; Rohrer et al., 1991; Yen et al., 2006). To our surprise, we
found no increases of TR target genes in MHC-hAR hearts
compared to WT (Figure 6C). To determine whether the lack of
increment in TR target genes was due to dysregulation of thyroid
hormones, we measured serum T3 and T4 levels and observed
no significant changes (Figure S4A). Next, we probed for the
expression of Lxrb and its target genes, Srebf1, Abca1, and
Abcg1 (Calkin and Tontonoz, 2012; Torra et al., 2008), and failed
to observe any increases (Figure 6D). Probing of the RAR target
genes, the CypP450 enzymes (Bray et al., 2001; Cai et al., 2002,
2003), revealed an upregulation of these genes in MHC-hAR
hearts compared to WT (Figure 6E). To confirm that increased
transcription of these RAR target Cyp genes was due to
decreased HDAC3 binding in their promoter region, we per-
formed ChIP studies and confirmed decreased HDAC3 binding
in MHC-hAR hearts (Figure 6F). Western blot analysis of nuclear
fractions from the heart revealed a significant increase in RARB
in the MHC-hAR mice whereas RARA, RXRA, and RXRB were
unchanged (Figure 6G). Because these mice express hAR spe-
cifically in the heart, there were no differences in RARB target
genes in the livers of MHC-hAR mice compared to WT (Fig-
ure S4B). This led us to conclude that hAR expression leads to
reduced HDAC3 corepressor complexes with consequent in-
creases in RARB in the nucleus and derepression of its target
gene expression. Because AR is a cytoplasmic enzyme and
HDAC3 resides both in the nucleus and cytoplasm, we per-
formed western blotting and determined that the cytoplasmic
HDAC3 was more prominently downregulated by AR than the
nuclear fraction (Figure 6H). This led us to conclude that the cyto-
plasmic HDAC3-corepressor complex formation is inhibited by
AR (Rajendran et al., 2011).
AR-mediated derepression of RARB targets in the absence of
the RARB ligand, all trans retinoic acid (RA), led us to hypothesize
that AR in the presence of the ligand would lead to hyper-activa-
tion of RARB targets as proposed in Figure 7. To test the hypoth-
esis at a preliminary level, we treated Ad-hARH9c2 cells with RA.
Indeed, we observed further increases in RARB target genes
with RA treatment as shown in Figure S4C. Reduced HDAC3-
corepressor complex leads to the activation of PPARg as well
as RARB, leading to the activation of target genes. Taken
together, these data support our hypothesis that AR plays a
key role in regulating nuclear receptor pathways.
DISCUSSION
HDAC3 plays an important role in the maintenance of car-
diac function through the regulation of substrate metabolism(left) and pull-down fraction subjected to western blot (right) showing reduced
indicated. Relative activity changes have been shown.
activity of AR was measured as nmoles of NADPH consumed per min per mg
Figure 5. DAD Supplementation Rescues HDAC3 Degradation
(A) Western blot analysis of site-directed mutants of AR-Flag in HEK293 cells using Flag antibody, normalized to actin.
(B) NCOR immunoprecipitated fraction on HEK293 lysates transfected with AR mutants was probed with Flag antibody.
(C) AR activity performed with purified recombinant proteins (n = 6).
(legend continued on next page)
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(Montgomery et al., 2008). Here, we show that AR interacts with
the DAD domain of nuclear corepressors NCOR1/SMRT,
thereby specifically attenuating their ability to regulate HDAC3
levels. Chief metabolic consequences of this interaction include
induction of PPARg and a host of genes that mediate accu-
mulation of pathological amounts of lipid. Increasing the
concentrations of NCOR1 restored HDAC3 levels and its down-
stream effects. Concomitantly, AR-mediated reductions in the
HDAC3-corepressor complex led to derepression of RARB
target genes. We demonstrate a link between the glucose-
metabolizing enzyme, AR, and transcriptional regulation via nu-
clear receptors through the HDAC3-corepressor complex.
Ectopic lipid accumulation in the heart is one of the major
mechanisms underlying cardiac failure in diabetic conditions
(Kankaanpa¨a¨ et al., 2006; Montani et al., 2004; Ruberg et al.,
2010). Accumulation of long chain acyl CoAs (substrate for cer-
amide synthesis) and ceramides have been implicated in lipo-
toxic cardiomyopathy (Gao et al., 2015; Park et al., 2008). In
this study, we observed a 2-fold increase in cardiac triglyceride
levels along with increased ceramide species and acyl carni-
tines, suggesting a lipotoxic-like environment in hAR-expressing
cardiac cells and tissues.
In both cell andmousemodels, we show reduced HDAC activ-
ity, HDAC3 levels, PPARg activation, and increased H4K8Ac
modification by hAR. The increased acetylation of histone H4
at both H4K5 and H4K8 along with reduced HDAC3 levels are
consistent with the earlier observations that the HDAC3/NCOR
complex favors histone H4 rather than H3 (Bhaskara et al.,
2008; Hartman et al., 2005; Knutson et al., 2008). Though
HDAC3 belongs to the class I HDAC family, it is essential for
the enzymatic activity for class II HDAC family members, specif-
ically HDAC 4, 5, and 7 (Fischle et al., 2001, 2002). Hence, the
decrease in HDAC3 protein mediated by hAR, that we observed,
contributes to the reduced activity of both class I and class II
HDACs. Taken together, these observations strengthen our hy-
pothesis that AR-mediated increases in acetyl H4 are likely to
be secondary to decreased HDAC3/NCOR complex.
It is well established that PPARg is a master transcriptional
regulator of lipid metabolism and that HDAC3 functions as a
repressor of PPARg (Gao et al., 2006; Jiang et al., 2014; Tian
et al., 2014). In the heart, modulation of PPARg has been shown
to drive lipid accumulation (Duan et al., 2005; Fajas et al., 2002;
Fu et al., 2005; Lai et al., 2008; Son et al., 2007, 2010; Marfella
et al., 2009a, 2009b). In our study, we show that both PPARg
expression and activity are upregulated in hAR-expressing
hearts, whereas in mice lacking AR, PPARg is downregulated.
Though increased PPARg activity is well characterized by the
degradation of its repressor, HDAC3, the potential mechanism
by which Pparg mRNA expression increases in hAR-expressing
cells is likely to be complex. We speculate that the change in(D) HDAC activity performed with purified recombinant proteins and relative H
transduced with mock- or Ncor1-expressing viral particles and were selected fo
Ad-GFP or Ad-hAR.
(E) Representative western blot analysis of cell lysates.
(F) qRT-PCR analysis on Pparg and its target genes (n = 6–9).
(G) Triglyceride measurements were made in H9c2 cells (n = 5).
(H) Representative western blot analysis on the theophylline (10 mM) treated and
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and consequently Tnf-a level. Tnf-a increases may mediate the
increase in Pparg mRNA expression (Figure S4D) as demon-
strated earlier in other studies (Guo et al., 2013; Jin et al.,
2014; Liu et al., 2012; Qiao et al., 2011; Yamaguchi et al., 2008).
Consistent with generalized effects of the hAR pathway, our
data revealed that hAR mediates HDAC3 reduction and
increased PPARg activation in other tissues and cell lines distinct
from the heart. Further, aging has been shown to increase lipid
accumulation in various tissues, including the heart (Petersen
et al., 2003; Unger, 2005). Our earlier studies showed that AR
expression and activity are upregulated in aging hearts (Anan-
thakrishnan et al., 2011). Here, we show increased cardiac tri-
glycerides along with reduced HDAC3 activity in aging hearts,
thus providing a potential AR-driven mechanism of HDAC3
reduction and lipid accumulation in this setting.
Our study shows that AR interacts with the DAD of NCOR1/
SMRT complex, leaving free, unstable HDAC3 to be degraded
as reported earlier (Guo et al., 2012). HDAC3 undergoes ubiqui-
tin-mediated proteasomal degradation, and this degradation is
essential for the transcriptional activation of nuclear hormones
as well as transcription factors like TR, RAR, PPARg, and
NF-kB (Perissi et al., 2004; Zhao et al., 2010). Among the protea-
some inhibitors tested, only bortezomib rescued HDAC3 from
cleavage. This could be due to their sensitivity toward Cyp450
enzymes. AR induced many of the RAR target genes, such as
the Cyp450 enzymes including Cyp3a4. It has previously been
shown that bortezomib is insensitive to Cyp3a4, whereas
MG132 and epoxomicin are degraded by the action of Cyp3a4
enzymes (Lee et al., 2010). Rescue of HDAC3 from degradation
by bortezomib confirms that the degradation is via the ubiquitin-
mediated proteasome pathway. Though our study strongly
supports that AR-mediated HDAC3 downregulation due to
degradation via proteosomal pathways, the role of post-tran-
scriptional or translational mechanisms as contributors to this
HDAC3 downregulation cannot be ruled out.
AR interaction with corepressors not only restricts complex
formation but also reduces the activity in vitro. The presence of
AR reduced HDAC3 activity by 10%; however, the effect of AR
on HDAC3 activity is very low. This indicates that the affinity of
HDAC3 for DAD is greater compared to the affinity of AR for
DAD. It is important to note that the HDAC3-DAD complex was
already formed and used for the assay, which might not be the
actual scenario in vivo in the cellular milieu. HDAC3 is synthe-
sized and subjected to degradation continuously in the cyto-
plasm, and the degradation is inhibited by its interaction with
either of its corepressors NCOR1 or SMRT. Apart from HDAC3
and corepressors, the HDAC3-corepressor complex consists
of proteins including GPS2, TBL1, and TBL1XR (Li and Wang,
2008; Oberoi et al., 2011; Zhang et al., 2006). GPS2 has beenDAC activity changes has been shown (n = 9). H9c2 cells were retrovirally
r 15 days with puromycin. Stably expressing cells were then transduced with
untreated MHC-hAR heart lysates (n = 4).
Figure 6. AR Derepresses RAR Target Genes
(A) Immunoprecipitation of Ad-mock or Ad-hAR-transduced cell lysates using SMRT antibody and western blot analysis performed with HDAC3 antibody. AR
expression and SMRT pull-down fractions were shown below.
(B–E) qRT-PCR analysis on cardiac tissues (B) for the expression of cofactors of nuclear corepressor complex, (C) TR target genes, (D) LXR target genes, and (E)
RAR target genes (n = 6 mice/group).
(legend continued on next page)
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Figure 7. Schematic Model of AR-Mediated Derepression of RAR Target Genes
(A–D) In unliganded condition, nuclear receptor RARB bound to HDAC3-nuclear corepressor complex and remains inactive and represses the target genes.
During activation, i.e., in the presence of ligand, all trans retinoic acid (atRA), RARB is relieved from the corepressor complex. LigandedRARB binds to coactivator
complexes along with transcription factors (TFs) and activates the target gene expression. In the presence of AR, nuclear corepressor binds to AR and free
HDAC3 is subjected to proteolytic cleavage. Though the coactivator fails to bind RARB, transcriptional machinery binds and activates the basal transcription,
termed as derepression. When both ligand and AR is present, hyperactivation of RAR target genes is observed. This is achieved because of enhanced
degradation of nuclear corepressor complexes (AR effect) combined with RARB activation (ligand effect) to reach the hyperactive state.reported to interact with various transcriptional factors including
p53, LXR, MSH4, and MSH5. The role of GPS2 in both activation
and repression complexes is poorly understood (Jakobsson
et al., 2009; Lee et al., 2006; Peng et al., 2001). Both TBL1 and
TBLR1 possess F-box-like motifs, which mediate interaction
with ubiquitin ligases. Like GPS2, both TBL1 and TBLR1 are
also involved in transcriptional activation (Adikesavan et al.,
2014; Li andWang, 2008; Perissi et al., 2004). AR downregulates
the expression of all three cofactors of the corepressor complex.(F) ChIP assay performed using HDAC3 antibody in heart tissues of wild-type an
were used (n = 4 mice/group).
(G) Representative western blot using nuclear lysates of wild-type and MHC-hA
RARB (n = 6–9 mice/group). Results were normalized to TBP.
(H) Western blots analysis on cytoplasmic and nuclear fractions for the expressio
Smooth muscle alpha actin (SMAA) was used as loading control.
See also Figure S4.
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formation in two ways: (1) AR competes with HDAC3 for its inter-
action with the corepressor, leading to free HDAC3 for degrada-
tion, and (2) AR leads to downregulation of all accessory factors
required for corepressor complex formation including Gps2,
Tbl1, and Tbl1xr.
Our result that downregulation of HDAC3 mediated by AR is
more pronounced in the cytoplasm is consistent with earlier find-
ings, which showed that the association and dissociation of thed MHC-hAR mice. For negative control, Serca2A and Ncx.1 promoter regions
R mice for the expression of nuclear receptors like RXRA, RXRB, RARA, and
n of HDAC3. VCAM1 and nucleolin were used as localization-specific controls.
HDAC3-NCOR complexes take place mostly in the cytoplasm
(Rajendran et al., 2011). The HDAC3-corepressor complex re-
presses several nuclear receptors like TR, RXR, RAR, VDR,
AR, GR, PXR (pregnane X receptor), and LXR (Dwivedi et al.,
1998; Shang et al., 2000; Wagner et al., 2003; Zhang et al.,
1998). One of the targets of HDAC3-corepressor complex is
circadian rhythmic genes, and RT-PCR array on these genes in
hAR-expressing heart tissues failed to show any changes (Fig-
ure S4E). In our study, though we have shown low HDAC3-core-
pressor complex formation, derepression is specific to PPARg
and RARB, altering lipid and retinoid metabolism. The relation-
ship between lipid and retinoid metabolism in the heart is
unclear, though recent studies suggest that both pathways are
interlinked (Kim et al., 2015; Lee et al., 2014).
In conclusion, our study reveals a key role for AR as a dissoci-
ation factor of the HDAC3-corepressor complex via interaction
with the DAD domain, thereby derepressing target gene expres-
sion, mimicking the liganded PPARg and RAR state. Our findings
define mechanism of AR-mediated lipid accumulation and indi-
cate that AR, via its ability to dissociate the HDAC3-corepressor
complexes, may function as a regulator of RA pathways.
EXPERIMENTAL PROCEDURES
Animals Used
All animal experimentations were approved by the Institutional Animal Care
and Use Committee at New York University School of Medicine. MHC-hAR,
TghAR, and ARKO and wild-type littermates mice were used as described
earlier (Gabbay et al., 2010; Hwang et al., 2004; Son et al., 2012).
Cell Culture
H9c2, HEK293, HUVEC, and HAEC cells were purchased from ATCC. For
adenoviral transduction, adenoviral particles encoding GFP or hAR (Vector
Biolabs) was used at a concentration of 0.5 3 109 pfu/ml.
Adipogenesis PCR Array
PCR array was performed and the data analyzed as per manufacturer’s proto-
col (SABiosciences Mouse adipogenesis PCR array).
Serum and tissue triglyceride and free fatty acid measurements were made
using commercially available kits from Wako chemicals and Biovision, as per
manufacturer instructions.
Recombinant Proteins
For experiments mentioned in Figure 4F, r.AR purchased from Wako Pure
Chemicals Industries was used. HDAC3 (transomic) and SMRT-DAD cDNA
(a kind gift from Dr. J.W. Schwabe) were subcloned in pET-Duet1 vector
(Novagen). SMRT-DAD cDNA had His tag, and hence, HDAC3-SMRT-DAD
complex was purified using Ni-NTA agarose beads (Invitrogen). The expres-
sion of both proteins was verified through western blot. For the reagents
mentioned in Figures 4H and 5C, hAR and L289A AR cDNA (transomic) were
subcloned in pET28b vector and purified using Ni-NTA agarose beads. For ex-
periments mentioned in Figures 4G and 5D, r.HDAC3 (Active Motif), SMRT-
DAD (Active Motif), r.AR (Wako), r.ABCG1 (Active Motif), and BSA (Sigma)
were used. hAR cDNA (transomic) was subcloned in pcDNA3.1Myc HisA vec-
tor in fusion with Flag tag at the C-terminal end. The plasmid was used to
create site-directed mutagenesis T287A, L289A, and L291A clones using
site-directed mutagenesis kit (Invitrogen). Flag antibody used for immunopre-
cipitation was obtained from Sigma.
HDAC activity in tissue and cell lysates was measured using fluorometric
activity assay kit (Caymen Chemicals). HAT activity was performed using
HAT activity assay kit (Biovision). Cytoplasmic and nuclear fractionations
were prepared using kit (Thermo Scientific) as per manufacturer’s protocol.
Proteins were quantified using BCA reagent (Bio-Rad).Competitive Binding Assay
Equal amount of HDAC3-DAD-His complex was incubated with increasing
amounts of AR using binding buffer (40 mM HEPES, 5% glycerol, 100 mM
KCl, 1 mM DTT, 10 mM MgCl2, and 1 mM ATP) at room temperature for
30 min. Ni-NTA agarose beads were blocked using BSA (1 mg/ml) for 1 hr
and then washed three timeswith the binding buffer. DADwas pulled down us-
ing Ni-NTA beads for 2 hr and then subjected to western blot for detecting AR.
Fatty Acid Uptake and Oxidation in Hearts
Freshly isolated hearts were subjected to a retrograde Langendorff perfusion
in KH buffer containing 5 mM glucose and 0.4 mmol/l palmitate and [9,10-3 H]
palmitate (80,000 dpm/ml) prebound to 0.4 mmol/l fatty acid-free BSA as
described in Hwang et al. (2004). [9, 10-3H] palmitate uptake (Kienesberger
et al., 2012) and oxidation rates were measured as published in the literature
(Kuang et al., 2004; Larsen et al., 1999). In the Pymol program, snapshots
were taken with molecular visualization software PyMOL initiated from 2DUX
(AR) and 4A69 (HDAC3) PDB structures. Using the display option of secondary
structure cartoon residues, 9–49 aa from 4A69 and 299–312 aa (2DUX) were
overlapped (Watson et al., 2012; Wilson et al., 1993).
Mass Spectrometry
Acyl carnitines and ceramides were quantified by liquid chromatography-elec-
tron spray ionization-tandem mass spectrometry (LC/ESI-MS/MS) in the mul-
tiple reaction monitoring (MRM) mode as previously described (Kasumov
et al., 2010; Umemoto et al., 2012).
Statistical Methods
Data were analyzed using INSTAT (GraphPad) software. Differences between
groups were assessed using ANOVA for repeated-measures, with subsequent
student-Newman-Keuls multiple comparisons post-test if the p value for
ANOVA was significant. All data are expressed as mean + SEM.
Detailed methods sections are available in Supplemental Information.
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